163 related articles for article (PubMed ID: 15908423)
21. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.
Wang C; Ivanov A; Chen L; Fredericks WJ; Seto E; Rauscher FJ; Chen J
EMBO J; 2005 Sep; 24(18):3279-90. PubMed ID: 16107876
[TBL] [Abstract][Full Text] [Related]
22. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress.
Grönroos E; Terentiev AA; Punga T; Ericsson J
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12165-70. PubMed ID: 15295102
[TBL] [Abstract][Full Text] [Related]
23. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
[TBL] [Abstract][Full Text] [Related]
24. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
25. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Pääjärvi G; Roudier E; Crisby M; Högberg J; Stenius U
FASEB J; 2005 Mar; 19(3):476-8. PubMed ID: 15625077
[TBL] [Abstract][Full Text] [Related]
26. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells.
Alazzouzi H; Suriano G; Guerra A; Plaja A; Espín E; Armengol M; Alhopuro P; Velho S; Shinomura Y; González-Aguilera JJ; Yamamoto H; Aaltonen LA; Moreno V; Capellà G; Peinado MA; Seruca R; Arango D; Schwartz S
J Med Genet; 2007 Jan; 44(1):75-80. PubMed ID: 16825434
[TBL] [Abstract][Full Text] [Related]
27. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
[TBL] [Abstract][Full Text] [Related]
28. p300/MDM2 complexes participate in MDM2-mediated p53 degradation.
Grossman SR; Perez M; Kung AL; Joseph M; Mansur C; Xiao ZX; Kumar S; Howley PM; Livingston DM
Mol Cell; 1998 Oct; 2(4):405-15. PubMed ID: 9809062
[TBL] [Abstract][Full Text] [Related]
29. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
31. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
Ray RM; Bhattacharya S; Johnson LR
Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
[TBL] [Abstract][Full Text] [Related]
32. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance.
Kulikov R; Boehme KA; Blattner C
Mol Cell Biol; 2005 Aug; 25(16):7170-80. PubMed ID: 16055726
[TBL] [Abstract][Full Text] [Related]
33. Activation of p53 in MDM2-overexpressing cells through phosphorylation.
Gao C; Nakajima T; Taya Y; Tsuchida N
Biochem Biophys Res Commun; 1999 Nov; 264(3):860-4. PubMed ID: 10544021
[TBL] [Abstract][Full Text] [Related]
34. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53.
Jackson MW; Agarwal MK; Agarwal ML; Agarwal A; Stanhope-Baker P; Williams BR; Stark GR
Oncogene; 2004 May; 23(25):4477-87. PubMed ID: 15064747
[TBL] [Abstract][Full Text] [Related]
35. MDM2 does not influence p53-mediated sensitivity to DNA-damaging drugs.
McKenzie PP; McPake CR; Ashford AA; Vanin EF; Harris LC
Mol Cancer Ther; 2002 Oct; 1(12):1097-104. PubMed ID: 12481433
[TBL] [Abstract][Full Text] [Related]
36. Endogenous human MDM2-C is highly expressed in human cancers and functions as a p53-independent growth activator.
Okoro DR; Arva N; Gao C; Polotskaia A; Puente C; Rosso M; Bargonetti J
PLoS One; 2013; 8(10):e77643. PubMed ID: 24147044
[TBL] [Abstract][Full Text] [Related]
37. Regulation of p53 stability by Mdm2.
Kubbutat MH; Jones SN; Vousden KH
Nature; 1997 May; 387(6630):299-303. PubMed ID: 9153396
[TBL] [Abstract][Full Text] [Related]
38. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
39. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
40. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
